Ranibizumab: treatment in patients with neovascular age-related macular degeneration |
| |
Authors: | Pieramici Dante J Avery Robert L |
| |
Affiliation: | The California Retina Consultants and Research Foundation, 515 East Micheltorena St, Suite C, Santa Barbara, California 93103, USA. |
| |
Abstract: | Vascular endothelial growth factor (VEGF)-A is a major regulator of angiogenesis and vascular permeability implicated in the development of diseases involving pathological angiogenesis and increased vascular permeability, such as neovascular age-related macular degeneration (AMD). LUCENTIS (ranibizumab), a humanized antigen-binding fragment (Fab) that neutralizes all VEGF-A isoforms and their biologically active degradation products, was recently approved by the FDA. Ranibizumab is the first FDA-approved treatment for neovascular AMD that maintains or improves vision in > or = 90% patients and provides a > or = 15-letter improvement in visual acuity for a quarter to a third of patients with all choroidal neovascularisation subtypes. Ranibizumab was associated with a < or = 1.7% rate of key serious ocular adverse events, such as endophthalmitis and uveitis, in two pivotal Phase III trials. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|